Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells

Hormone Molecular Biology and Clinical Investigation

Volumn 7, Issue 1, 2011, Pages 265-272

  Lorenz, Viola ^a   Hessenkemper, Wiebke ^a   Rödiger, Julia ^a   Kyrylenko, Sergiy ^a,b,c   Kraft, Florian ^a   Baniahmad, Aria ^a,b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

cellular senescence; epigenetic modulators; neu roblastoma; prostate cancer cells

Indexed keywords

ANDROGEN; BUTYRIC ACID; CYCLIN D1; MESSENGER RNA; PROTEIN P16; PROTEIN P21; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR E2F1; VALPROIC ACID;

ANIMAL CELL; ARTICLE; CELL AGING; CONTROLLED STUDY; EPIGENETICS; HUMAN; HUMAN CELL; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; ONCOGENE C MYC; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTO ONCOGENE; SENESCENCE; UPREGULATION;

EID: 84908354783     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2011.020     Document Type: Article

References (45)

1. Muhlethaler-Mottet A., Meier R., Flahaut M., Bourloud KB., Nar-dou K., Joseph JM., Gross N. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 2008;7:55.
2. Glozak MA., Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-32.
3. Tan J., Cang S., Ma Y., Petrillo RL., Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5.
4. Xu WS., Parmigiani RB., Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26: 5541-52.
5. Secrist JP., Zhou X., Richon VM. HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 2003;4:1422-7.
6. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-6.
7. Villar-Garea A., Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 2004;112:171-8.
8. Dokmanovic M., Perez G., Xu W., Ngo L., Clarke C., Parmigiani RB., Marks PA. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007;6:2525-34.
9. Gurney JG., Ross JA., Wall DA., Bleyer WA., Severson RK., Robison LL. Infant cancer in the US: histology-specific incidence and trends., 1973 to 1992. J Pediatr Hematol Onc 1997; 19:428-32.
10. London WB., Castleberry RP., Matthay KK., Look AT., Seeger RC., Shimada H., Thorner P., Brodeur G., Maris JM., Reynolds CP., Cohn SL. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23:6459-65.
11. Schwab M., Alitalo K., Klempnauer KH., Varmus HE., Bishop JM., Gilbert F., Brodeur G., Goldstein M., Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8.
12. Moley JF., Brother MB., Wells SA., Spengler BA., Biedler JL., Brodeur GM. Low frequency of ras gene mutations in neuro-blastomas, pheochromocytomas., and medullary thyroid cancers. Cancer Res 1991;51:1596-9.
13. Oehme I., Deubzer HE., Wegener D., Pickert D., Linke JP., Hero B., Kopp-Schneider A., Westermann F., Ulrich SM., von Deim-lingen A., Fischer M., Witt O. Histone deacetylase 8 in neuro-blastoma tumorigenesis. Clin Cancer Res 2009;15:91-9.
14. Ogryzko VV., Hirai TH., Russanova VR., Barbie DA., Howard BH. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol 1996;16:5210-8.
15. Xiao H., Hasegawa T., Miyaishi O., Ohkusu K., Isobe K. Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIP1 in p53-independ-ent manner. Biochem Bioph Res Co 1997;237:457-60.
16. Schmitt CA. Senescence., apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer 2003;3:286-95.
17. Campisi J. Senescent cells., tumor suppression., and organismal aging: good citizens., bad neighbors. Cell 2005;120:513-22.
18. Brinkmann AO., Trapman J. Prostate cancer schemes for androgen escape. Nat Med 2000;6:628-9.
19. Bray F., Sankila R., Ferlay J., Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002;38:99-166.
20. Kuefer R., Genze F., Zugmaier W., Hautmann RE., Rinnab L., Gschwend JE., Angelmeier M., Estrada A., Buechele B. Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer. Neoplasia 2007;9:246-53.
21. Dimri GP., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano EE., Linskens M., Rubelj I., Pereira-Smith O., Peacocket M., Campisi J. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363-7.
22. Abramova MV., Svetlikova SB., Aksenov ND., Pospelova TV., Pospelov VA. Histone deacetylase inhibitor blocks proliferation of cells transformed with oncogenes E1A and cHa-ras. Tsito-logiya 2003;45:1100-8.
23. Zubova Iu G., Bykova TV., Zubova SG., Abramova MV., Aksenov ND., Pospelov VA., Pospelova TV. Induction of premature senescence program by an inhibitor of histone deacetylase sodium butyrate in normal and transformed rat fibroblasts. Tsito-logiya 2005;47:1055-62.
24. Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007;1775:5-20.
25. Pan JS., Hong MZ., Ren JL. Reactive oxygen species: a double-edged sword in oncogenesis. World J Gastroentero 2009;15: 1702-7.
26. Mikhailov A., Shinohara M., Rieder CL. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol 2004;166:517-26.
27. Choi JH., Kwon HJ., Yoon BI., Kim JH., Han SU., Joo HJ., Kim DY. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-4.
28. Kawai H., Li H., Avraham S., Jiang S., Avraham HK. Overex-pression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 2003;107:353-8.
29. Halkidou K., Gaughan L., Cook S., Leung HY., Neal DE., Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59:177-89.
30. Bolden JE., Peart MJ., Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5: 769-84.
31. Minucci S., Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
32. Gey C., Kyrylenko S., Hennig L., Nguyen LH., Buttner A., Pham HD., Giannis A. Phloroglucinol derivatives guttiferone G., aris-toforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2. Angew Chem Int Ed Engl 2007;46:5219-22.
33. Place RF., Noonan EJ., Giardina C. HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol 2005;6:37.
34. Wintersberger E., Mudrak I., Wintersberger U. Butyrate inhibits mouse fibroblasts at a control point in the G1 phase. J Cell Biochem 1983;21:239-47.
35. Philippe J., Drucker DJ., Chick WL., Habener JF. Transcriptional regulation of genes encoding insulin., glucagon, and angioten-sinogen by sodium butyrate in a rat islet cell line. Mol Cell Biol 1987;7:560-3.
36. Nakagawa T., Nelkin BD., Baylin SB., de Bustros A. Transcrip-tional and posttranscriptional modulation of calcitonin gene expression by sodium n-butyrate in cultured human medullary thyroid carcinoma. Cancer Res 1988;48:2096-100.
37. Toscani A., Soprano DR., Soprano KJ. Molecular analysis of sodium butyrate-induced growth arrest. Oncogene Res 1988;3: 223-38.
38. Charollais RH., Buquet C., Mester J. Butyrate blocks the accumulation of CDC2 mRNA in late G1 phase but inhibits both the early and late G1 progression in chemically transformed mouse fibroblasts BP-A31. J Cell Physiol 1990;145:46-52.
39. Glauber JG., Wandersee NJ., Little JA., Ginder GD. 5'-flanking sequences mediate butyrate stimulation of embryonic globin gene expression in adult erythroid cells. Mol Cell Biol 1991; 11:4690-7.
40. Karlsen AE., Fujimoto WY., Rabinovitch P., Dube S., Lernmark A. Effects of sodium butyrate on proliferation-dependent insulin gene expression and insulin release in glucose-sensitive RIN-5AH cells. J Biol Chem 1991;266:7542-8.
41. Wu CH., van Riggelen J., Yetil A., Fan AC., Bachireddy P., Fel-sher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA 2007;104:13028-33.
42. Guney I., Wu S., Sedivy JM. Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci USA 2006;103:3645-50.
43. Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., Möröy T., Bartek J., Massagué J., Hänel F., Eilers M. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001;3:392-9.
44. Xiong Y., Hannon GJ., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366:701-4.
45. Passos JF., Nelson G., Wang C., Richter T., Simillion C., Proctor CJ., Miwa S., Olijalagers S., Hallinan J., Wipat A., Saretzki G., Rudolph KL., Kirkwood TBL., von Zglinicki T. Feedback between p21 and reactive oxygen production is necessary for cell senescence. Mol Syst Biol 2010;6:347.